GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » Operating Cash Flow per Share

Lantheus Holdings (FRA:0L8) Operating Cash Flow per Share : €4.28 (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Operating Cash Flow per Share?

Lantheus Holdings's operating cash flow per share for the three months ended in Mar. 2024 was €1.67. Lantheus Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €4.28.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Lantheus Holdings was -14.80% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 143.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Lantheus Holdings's Operating Cash Flow per Share or its related term are showing as below:

FRA:0L8' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -40.1   Med: 15   Max: 143
Current: 143

During the past 13 years, Lantheus Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was 143.00% per year. The lowest was -40.10% per year. And the median was 15.00% per year.

FRA:0L8's 3-Year OCF Growth Rate is ranked better than
98.64% of 806 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs FRA:0L8: 143.00

Lantheus Holdings Operating Cash Flow per Share Historical Data

The historical data trend for Lantheus Holdings's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Operating Cash Flow per Share Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.80 0.25 0.71 3.76 3.99

Lantheus Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 -0.42 1.56 1.47 1.67

Competitive Comparison of Lantheus Holdings's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Price-to-Operating-Cash-Flow falls into.



Lantheus Holdings Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Lantheus Holdings's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=279.923/70.239
=3.99

Lantheus Holdings's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=117.059/70.095
=1.67

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (FRA:0L8) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines